- Home
- SHFS vs CANF Comparison
SHFS vs CANF Comparison
Compare SHFS & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHFS
- CANF
- Stock Information
- Founded
- SHFS 2015
- CANF 1994
- Country
- SHFS United States
- CANF Israel
- Employees
- SHFS N/A
- CANF N/A
- Industry
- SHFS Finance: Consumer Services
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- SHFS Finance
- CANF Health Care
- Exchange
- SHFS Nasdaq
- CANF Nasdaq
- Market Cap
- SHFS 9.5M
- CANF 9.6M
- IPO Year
- SHFS N/A
- CANF N/A
- Fundamental
- Price
- SHFS $2.74
- CANF $0.44
- Analyst Decision
- SHFS
- CANF Strong Buy
- Analyst Count
- SHFS 0
- CANF 2
- Target Price
- SHFS N/A
- CANF $14.50
- AVG Volume (30 Days)
- SHFS 76.8K
- CANF 294.8K
- Earning Date
- SHFS 11-12-2025
- CANF 11-27-2025
- Dividend Yield
- SHFS N/A
- CANF N/A
- EPS Growth
- SHFS N/A
- CANF N/A
- EPS
- SHFS N/A
- CANF N/A
- Revenue
- SHFS $11,720,493.00
- CANF $560,000.00
- Revenue This Year
- SHFS N/A
- CANF $461.72
- Revenue Next Year
- SHFS N/A
- CANF N/A
- P/E Ratio
- SHFS N/A
- CANF N/A
- Revenue Growth
- SHFS N/A
- CANF N/A
- 52 Week Low
- SHFS $1.84
- CANF $0.43
- 52 Week High
- SHFS $10.53
- CANF $2.50
- Technical
- Relative Strength Index (RSI)
- SHFS 36.04
- CANF 25.97
- Support Level
- SHFS $2.77
- CANF $0.46
- Resistance Level
- SHFS $3.52
- CANF $0.49
- Average True Range (ATR)
- SHFS 0.40
- CANF 0.03
- MACD
- SHFS -0.19
- CANF -0.00
- Stochastic Oscillator
- SHFS 6.38
- CANF 3.76
About SHFS SHF Holdings Inc.
SHF Holdings Inc is a financial services provider to cannabis-related businesses. It offers reliable access to banking solutions for cannabis, hemp, CBD, and ancillary operators, making communities safer, driving growth in local economies, and fostering long-term partnerships. The group, through its financial institution clients, implements accountability, transparency, monitoring, reporting, and risk mitigation measures while meeting Bank Secrecy Act obligations in line with FinCEN guidance on cannabis-related businesses. Its services include Program Management Support, Customer Generation, Ongoing Program Auditing, and Compliance Monitoring, among others.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).